Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS

The study investigated 123 metastatic ovarian cancer patients over two and a half years using the Parsortix system to assess 474 longitudinal patient samples

Downstream qPCR molecular analysis of the Parsortix harvest for ESR1 and ERCC1 genes may be an early predictor of progression free survival and cancer progression respectively

GUILDFORD, SURREY / ACCESSWIRE / May 16, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of a study using the Parsortix® system to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer (PROC) patients. The study was conducted as an offshoot of the European multi-centre GANNET53 Phase II clinical trial (NCT02012192) funded by the EU 7th Framework Programme (Grant agreement ID: 602602). The study investigated the efficacy of ganetespib in combination with paclitaxel vs. paclitaxel alone. Patients were enrolled across 12 clinical centres in Germany, Belgium, France, and Austria.

The translational study, which the research team believes is the largest study of CTCs in ovarian cancer (in terms of number of patient samples analysed), was conducted by researchers at the Medical University of Vienna, Austria. The study analysed a total of 474 blood samples collected from 123 PROC patients at baseline (i.e. prior to first administration of study drugs), and at multiple timepoints over a period of two and a half years during treatment until disease progression. A panel of 27 gene transcripts (RNA) was analysed on Parsortix-harvested CTCs using standard laboratory qPCR analysis.

The authors identified two CTC-associated markers with potential prognostic value. ERCC1, a key gene of the DNA damage response pathway, was associated with an increased risk of disease progression and worse outcomes, whereas the presence of ESR1, a gene encoding oestrogen receptor alpha (ERα), was associated with a reduced progression risk. The presence of ESR1 transcripts together with concurrent absence of ERCC1 transcripts in CTC-enriched samples at baseline and during treatment cycles was found to be predictive of improved progression free survival (PFS). Whereas the presence of ERCCI transcripts and the absence of ESR1 transcripts at baseline and during treatment cycles indicated a 12.77× greater likelihood (odds ratio) of cancer progression.

The analysis of these biomarkers has the potential to provide an early indication of PFS ahead of clinical trial results and suggests that CTC characterisation may be a valuable tool for pharma drug trials in the future.

In addition, the authors conclude that molecular characterisation of CTCs before and during treatment has the potential to be a useful tool to monitor ovarian cancer patients and may provide further insights into the biology of this difficult to treat disease. According to clinicaltrials.gov there are 1,024 active interventional studies enrolling more than 825,000 participants in ovarian cancer.

The study is published as a peer-reviewed journal article in the International Journal of Cancer and is available online at https://angleplc.com/publications/.

ANGLE Chief Scientific Officer, Karen Miller, commented:
"We are pleased to share this peer-reviewed publication by the Medical University of Vienna and the European GANNET53 consortium. The paper demonstrates the potential utility of molecular characterisation of CTCs enriched using the Parsortix system in monitoring ovarian cancer patients throughout their treatment and during follow-up. The scale of this study, both in terms of numbers of patients and timescale of follow-up, is particularly important. It clearly demonstrates how use of the Parsortix system in cancer trials could in the future enable our pharma customers to gain an early understanding of how patients are responding to their drug."

Ovarian cancer accounted for over 320,000 new cases of cancer, and over 200,000 deaths worldwide in 20221. Diagnosis often occurs at a later stage, and although patients often respond well to initial treatment with a platinum-based chemotherapy, many patients relapse and develop resistance to treatment2.

1. American Cancer Society. Global Cancer Facts & Figures 5th Edition. Atlanta: American Cancer Society; 2024
2. Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022; 14:e30561

For further information:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive
Ian Griffiths, Finance Director

Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser

+44 (0) 20 3207 7800

FTI Consulting
Simon Conway, Ciara Martin
Matthew Ventimiglia (US)


+44 (0) 203 727 1000
+1 (212) 850 5624

For Research Use Only. Not for use in diagnostic procedures.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.

Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc



View the original press release on accesswire.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.